Paychex Reports In-Line Q1 Revenue as Shares Slip on Cautious Outlook

Paychex reported fiscal first-quarter 2027 revenue of $1.63 billion on Wednesday, matching the FactSet consensus estimate of $1.63 billion, but shares fell as investors focused on the company's cautious forward guidance and a challenging environment for small and midsize business clients. The results covered the quarter ended August 31, 2026, and were released before markets opened. The stock had already declined roughly 5.2% in the month leading up to the report amid tempered analyst sentiment.

Wednesday's broader options market reflected elevated activity across several large-cap names. Apple saw 786,800 contracts change hands, representing approximately 78 million underlying shares. Broadcom traded 230,161 contracts, equal to roughly 23 million underlying shares and about 84.3% of its recent average daily options volume. Fair Isaac Corp saw 1,946 contracts trade, representing about 194,600 underlying shares and approximately 49.7% of its average daily volume. Stocks with rising options interest included Micron, Intel, SoFi, MicroStrategy, GameStop, Bank of America, Netflix, and Oracle.

Netlist shares jumped sharply on Wednesday, extending a rally that has taken the stock up more than 667% year to date through late September 2026. The memory-technology company has benefited from a Samsung supply and licensing alliance and improving earnings estimates, though a U.S. appeals court earlier in the month upheld rulings invalidating five of Netlist's memory patents in litigation against Micron.

Rapport Therapeutics, a clinical-stage biotech developing small-molecule precision medicines for neurological and psychiatric disorders, saw its stock slide Wednesday. The company uses a receptor-associated protein platform to generate precision drug candidates, and the decline appeared tied to investor reassessment of its clinical pipeline risk rather than any announced data readout.